Genetics and new approaches to cancer therapy

Carcinogenesis

Volumn 23, Issue 5, 2002, Pages 683-686

  Cavenee, Webster K ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CASPASE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMUNOTOXIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTYROSINE; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; PROTEIN SHC; RAS PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENICITY; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; GENE ACTIVITY; GENE CONTROL; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SRC HOMOLOGY DOMAIN; TREATMENT PLANNING; TUMOR BIOPSY; VIRAL GENE DELIVERY SYSTEM;

EID: 0036264843     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.5.683     Document Type: Article

References (33)

1. Advances in the molecular genetics of gliomas
2. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
3. The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target
4. Molecular pathogenesis of malignant gliomas
5. Structural alterations of the epidermal growth factor receptor gene in human gliomas
6. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
7. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas
8. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
9. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma
10. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate and mitogen-activated protein kinase in human glioblastoma multiforme specimens
11. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
12. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
13. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling
14. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody
15. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)
16. The intracellular tyrosine kinase domain of the epidermal growth factor receptor undergoes a conformational change upon autophosphorylation
17. PTB domain binding to signaling proteins through a sequence motif containing phosphotyrosine
18. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
19. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway
20. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor
21. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene
22. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer
23. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
24. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
25. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
26. Sensitization of human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth receptor to cisplatin by the AG1478 tyrosine kinase inhibitor
27. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
28. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
29. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate
30. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin
31. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine parent
32. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of MAb806, a novel monoclonal antibody directed to the receptor
33. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR